|
|
Post by jpg on Apr 8, 2014 6:40:19 GMT -5
|
|
|
|
Post by thekindaguyiyam on Apr 9, 2014 12:20:17 GMT -5
With the FDA knowing this is advance it; it makes the delay of Afrezza easier to accept. It would make good sense on the heals of this Actos failure and a diabetes drug that 3 month review would be prudent from the FDA's point of view. Also with one less medication available to patients; the need for improvement has increased: Afrezza Iyam |
|
|
|
Post by otherottawaguy on Apr 9, 2014 12:49:50 GMT -5
Aren't these the guys that we supposedly licensed that Cancer indication sidejob to? OOG |
|
|
|
Post by jpg on Apr 9, 2014 13:13:53 GMT -5
Aren't these the guys that we supposedly licensed that Cancer indication sidejob to? OOG Not certain I follow? I don't think Mannkind has any dealings with Takeda or Lilly? Corrections welcome. |
|
|
|
Post by otherottawaguy on Apr 9, 2014 13:42:05 GMT -5
|
|
|
|
Post by jpg on Apr 9, 2014 13:59:38 GMT -5
Never understood that one? Maybe we will soon (in the next year...) see if Tolero did anything to actually move this project forward. |
|
